The 2-year outcomes data from the EWOLUTION trial, which focused on clinical outcomes in patients with atrial fibrillation (AFib), were recently published in Circulation Arrhythmias and Electrophysiology. The study included 1,020 patients who received a WATCHMAN left atrial appendage closure device. The patient population was at a high risk for stroke and bleeding. According to the study results, stroke and bleeding rates were consistently lower rates of stroke and nonprocedural bleeding. During the two-year follow-up, 161 patients died, 22 strokes were reported, and 47 non-procedural bleeding events occurred. “During the complete 2-year follow-up of Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology, patients with a WATCHMAN left atrial appendage occlusion device had consistently low rates of stroke and nonprocedural bleeding, although most were contraindicated to oral anticoagulation and used only single antiplatelet therapy or nothing,” the researchers wrote in their conclusion.